Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report

Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report

Abstract Background Nintedanib is a tyrosine kinase inhibitor that efficiently slows the progression of idiopathic pulmonary fibrosis (IPF) and has an acceptable tolerability profile. In contrast, immune checkpoint inhibitors (ICIs) such as programmed death 1 and programmed death ligand 1 inhibitors...

Full description

Bibliographic Details
Main Authors: Hideaki Yamakawa, Tomohiro Oba, Hiroki Ohta, Yuta Tsukahara, Gen Kida, Emiri Tsumiyama, Tomotaka Nishizawa, Rie Kawabe, Shintaro Sato, Keiichi Akasaka, Masako Amano, Kazuyoshi Kuwano, Hidekazu Matsushima
Format: Article
Language:English
Published: BMC 2019-08-01
Series:BMC Pulmonary Medicine
Subjects:
Nintedanib
Immune checkpoint inhibitors
Drug-induced pneumonitis
Online Access:http://link.springer.com/article/10.1186/s12890-019-0920-9

Internet

http://link.springer.com/article/10.1186/s12890-019-0920-9

Similar Items